Background The SELENA flare index (SFI) has functioned well in clinical and clinical trial settings (1), but has the limitation that it classifies only severe versus combined mild/moderate flares.

Background: Rheumatoid arthritis (RA) flares remain poorly understood at a mechanistic level and have been difficult to study because of their sporadic nature. BIO-FLARE (BIOlogical Factors that Limit ...

Department of Internal Medicine, Division of Rheumatology, University of Maastricht, Maastricht, The Netherlands Correspondence to: Professor D van der Heijde Department of Internal Medicine, Division ...

Objective: To evaluate the efficacy and safety of adding sulfasalazine to leflunomide treatment compared with switching to sulfasalazine alone in patients with RA with an inadequate response to ...

Background Dermatomyositis (DM) is a rare, multi-system idiopathic inflammatory myopathy characterized by skin rash and muscle weakness that is often accompanied by pain and fatigue. Other ...